Investment Risk Analysis: APPLIGENICS LIMITED

1. Risk Rating: HIGH

Justification: The company is balance-sheet insolvent with net liabilities of £358,620 that have deteriorated by £83,782 in the latest year. While short-term liquidity appears adequate, the sustained and deepening negative equity position raises fundamental concerns about long-term viability, particularly given the minimal disclosure available under micro-entity filing requirements.

2. Key Concerns

Concern 1: Balance Sheet Insolvency

The company's net assets are negative £358,620 (2023: negative £274,838), meaning total liabilities exceed total assets by a significant margin. This deterioration of £83,782 in a single year represents a 30.5% worsening of the deficit. The long-term creditors due after one year stand at £463,918 against current assets of only £123,177. The company can only continue to trade if these long-term creditors—likely the director himself—continue to forbear enforcement.

Concern 2: Minimal Transparency (Micro-Entity Filing)

The company files as a micro-entity, which permits the most reduced disclosure permissible. There is no profit and loss account, no cash flow statement, and no breakdown of current assets between cash, debtors, and other categories. This makes it impossible to assess trading performance, cash generation capability, or the nature and recoverability of the asset base. The single-employee structure and absence of an audit further limit assurance.

Concern 3: Key-Person Dependency and Concentration of Control

Maurice Spillane serves as the sole director and holds between 50-75% of shares, between 50-75% of voting rights, and the right to appoint and remove directors. There is no board diversity, no apparent separation of ownership and control, and no counterbalancing governance structure. Any incapacity or withdrawal of support by this individual would likely precipitate immediate insolvency.

3. Positive Indicators

• Long Operating History: Incorporated in 1995, the company has operated for nearly 30 years, suggesting a degree of resilience and established market presence under its SIC classification (74909 - professional, scientific and technical activities).

• Adequate Short-Term Liquidity: Current assets (£123,177) comfortably exceed current liabilities (£17,879), yielding a current ratio of approximately 6.9x. This suggests no immediate cash flow crisis within the next 12 months.

• Regulatory Compliance: All filings are current—accounts are not overdue (next due 30 September 2026) and the confirmation statement is up to date. There is no evidence of disqualification orders against the director.

• Likely Director Support: The substantial share capital of £643,250 and the pattern of long-term creditors suggest the director has historically funded the business. The continuation of trade despite negative equity implies ongoing financial support from the controlling shareholder.

4. Due Diligence Notes

1. Nature of Long-Term Creditors: The £463,918 due after one year warrants urgent clarification. Determine whether this represents director loans, third-party debt, or other obligations. If these are director loans, the insolvency risk is mitigated by the likelihood of continued forbearance; if third-party debt, the risk profile is substantially worse.

2. Composition of Current Assets: The £123,177 in current assets requires breakdown. Is this primarily cash, trade debtors, or intercompany balances? The absence of fixed assets suggests this may be a consulting operation where the primary asset is the director's expertise, but the asset quality cannot be confirmed from micro-entity accounts alone.

3. Trading Profitability: Request management accounts to understand whether the company is generating operating profits. The deteriorating net asset position could indicate trading losses, dividend extraction, or asset write-downs—each carrying different risk implications.

4. Related-Party Transactions: Given the concentrated ownership, investigate whether there are related-party transactions not disclosed in micro-entity accounts, including any charges or security granted over assets.

5. Historical Shareholders' Funds Discrepancy: The financial history shows shareholders' funds of approximately negative £1.2 million for 2015-2017, which then aligns with net assets from 2018 onwards. Clarify whether a capital reorganisation, debt forgiveness, or accounting adjustment occurred around 2018 that altered the equity position.

6. Contingent Liabilities: Micro-entity accounts do not require disclosure of contingent liabilities or commitments. Investigate whether any guarantees, legal claims, or off-balance-sheet obligations exist.